Tuesday, 10 June 2014

Stemedica receives U.S. patent for cellular scaffold

Stemedica Cell Technologies Inc., a manufacturer of adult, allogeneic stem cells and stem cell factors, has received a new patent from the U.S. Patent & Trademark Office, US8709081 entitled “Cellular Scaffold.”

The patent, coupled with the US8105380 patent issued in 2012, extends Stemedica’s proprietary technology to therapeutic skin regeneration. The scaffolds are human skin equivalents that can be transplanted to regenerate skin in patients with skin defects, such as burn injuries, or diseases affecting skin, such as diabetic ulcers.

“Adding biologically active factors to Stemedica’s original, patented cellular scaffolds might increase the engrafting capability and the potency of engrafted cells. We expect our newly patented technology to enhance the overall performance of the scaffold and make it more competitive among available, human skin equivalents.” said Alex Kharazi, M.D., Ph.D., Chief Technology Officer of Stemedica.

Invented by Dr. Alex Kharazi, Dr. Ludmila Kharazi, Stemedica’s Senior Research Scientist, and Dr. Nikolai Tankovich, Stemedica’s President and Chief Medical Officer, the new patent contains stem cell factors derived from the cells to enhance cellular effect and modulate stem cell action. 

The cellular scaffolds are used in cell-based assays, and they detect in vitro effects of environmental factors and chemical factors on skin development. The invention relates to a layered cell scaffold that is seeded with mesenchymal and ectodermal cells, as well as molecules (collectively called stem cell factors) derived from those cells. The layered cellular scaffold comprises an inoculum of mesenchymal cells and ectodermal cells positioned between two opposing scaffolds in a sandwich configuration.

“Our newest patent is a significant achievement in tissue engineering, and it is another example of how Stemedica applies its expertise to push the boundary of what is possible with stem cells. Stemedica is designing truly regenerative medicine – treatments that address core problems rather than only alleviating symptoms. Our patented scaffolds are designed as multi-layer, multi-cell and multi-compound structures, which more closely resembles how real skin is structured. As a result the scaffolds respond more like human skin than anything we have yet seen. This presents tremendous opportunities for us to treat a significant number of skin pathologies and conditions.” said Nikolai Tankovich, M.D., Ph.D., FASLMS, President, Chief Medical Officer and Director of Stemedica.


No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !